Schwartz, F.H., Cai, Q., Fellmann, E. et al. (2017). TET2 mutations in B cells of patients affected by angioimmunoblastic T‐cell lymphoma. J Pathol 242 (2): 129–133.72 72 Nguyen, T.B., Sakata‐Yanagimoto, M., Asabe, Y. et al. (2017). Identification of cell‐type‐specific mutations in nodal T‐cell lymphomas. Blood Cancer J 7 (1): e516.
73 73 Bräuninger, A., Spieker, T., Willenbrock, K. et al. (2001). Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor‐deficient) epstein‐barr virus‐infected b cells in angioimmunoblastic t cell lymphoma. J Exp Med 194 (7): 927–940.
74 74 Cheminant, M., Bruneau, J., Kosmider, O. et al. (2015). Efficacy of 5‐Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol 168 (6): 913–916.
75 75 Tiacci, E., Venanzi, A., Ascani, S. et al. (2018). High‐risk clonal hematopoiesis as the origin of AITL and NPM1‐mutated AML. N Engl J Med 379 (10): 981–984.
76 76 Lemonnier, F., Dupuis, J., Sujobert, P. et al. (2018). Treatment with 5‐azacytidine induces a sustained response in patients with angioimmunoblastic T‐cell lymphoma. Blood 132 (21): 2305–2309.
77 77 Lamant, L., McCarthy, K., d’Amore, E. et al. (2011). Prognostic impact of morphologic and phenotypic features of childhood ALK‐positive anaplastic large‐cell lymphoma: results of the ALCL99 study. J Clin Oncol 29 (35): 4669–4676.
78 78 Geissinger, E., Odenwald, T., Lee, S.S. et al. (2004). Nodal peripheral T‐cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T‐cells. Virchows Arch 445 (4): 334–343.
79 79 Patsouris, E., Engelhard, M., Zwingers, T., and Lennert, K. (1993). Lymphoepithelioid cell lymphoma (Lennert's lymphoma): clinical features derived from analysis of 108 cases. Br J Haematol 84 (2): 346–348.
80 80 Ballester, B., Ramuz, O., Gisselbrecht, C. et al. (2006). Gene expression profiling identifies molecular subgroups among nodal peripheral T‐cell lymphomas. Oncogene 25 (10): 1560–1570.
81 81 Cuadros, M., Dave, S.S., Jaffe, E.S. et al. (2007). Identification of a proliferation signature related to survival in nodal peripheral T‐cell lymphomas. J Clin Oncol 25 (22): 3321–3329.
82 82 Aggarwal, D., Srivastava, G., Gupta, R. et al. (2012). Angiogenesis in non‐Hodgkin's lymphoma: an intercategory comparison of microvessel density. ISRN Hematol 2012: 943089.
83 83 Rabenhorst, A., Schlaak, M., Heukamp, L.C. et al. (2012). Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 120 (10): 2042–2054.
84 84 Zhang, W., Wang, L., Zhou, D. et al. (2011). Expression of tumor‐associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T‐cell lymphoma, not otherwise specified. Leuk Lymphoma 52 (1): 46–52.
85 85 Rafii, S., Lyden, D., Benezra, R. et al. (2002). Vascular and haematopoietic stem cells: novel targets for anti‐angiogenesis therapy? Nat Rev Cancer 2 (11): 826–835.
86 86 Tabbò, F., Ponzoni, M., Rabadan, R. et al. (2013). Beyond NPM‐anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol 20 (4): 374–381.
87 87 Salven, P., Orpana, A., Teerenhovi, L., and Joensuu, H. (2000). Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non‐Hodgkin lymphoma: a single‐institution study of 200 patients. Blood 96 (12): 3712–3718.
88 88 Ganjoo, K., Hong, F., Horning, S.J. et al. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T‐cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55 (4): 768–772.
89 89 Roufosse, F., Garaud, S., and de Leval, L. (2012). Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol 49 (2): 138–148.
90 90 Kleinhans, M., Tun‐Kyi, A., Gilliet, M. et al. (2003). Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T‐cell lymphoma. Blood 101 (4): 1487–1493.
91 91 Lacy, P. and Moqbel, R. (2000). Eosinophil cytokines. Chem Immunol 76: 134–155.
92 92 Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F. et al. (1980). Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T‐cell lymphoma. Proc Natl Acad Sci U S A 77 (12): 7415.
93 93 Matsuoka, M. (2003). Human T‐cell leukemia virus type I and adult T‐cell leukemia. Oncogene 22 (33): 5131–5140.
94 94 Bangham, C.R.M. (2018). Cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol 36: 43–71.
95 95 Bangham, C.R.M. and Ratner, L. (2015). How does HTLV‐1 cause adult T‐cell leukaemia/lymphoma (ATL)? Curr Opin Virol 14: 93–100.
96 96 Melamed, A., Laydon, D.J., Gillet, N.A. et al. (2013). Genome‐wide determinants of proviral targeting, clonal abundance and expression in natural HTLV‐1 infection. PLOS Pathogens 9 (3): e1003271.
97 97 Watanabe, T. (2017). Adult T‐cell leukemia: molecular basis for clonal expansion and transformation of HTLV‐1‐infected T cells. Blood 129 (9): 1071–1081.
98 98 Tabiasco, J., Vercellone, A., Meggetto, F. et al. (2003). Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 170 (12): 5993.
99 99 Lee, J.H., Choi, J., Ahn, Y.O. et al. (2018). CD21‐independent Epstein‐Barr virus entry into NK cells. Cell Immunol 327: 21–25.
100 100 Morales‐Sánchez, A. and Fuentes‐Pananá, E.M. (2014). Human viruses and cancer. Viruses 6 (10): 4047–4079.
101 101 Li, Z., Xia, Y., Feng, L.N. et al. (2016). Genetic risk of extranodal natural killer T‐cell lymphoma: a genome‐wide association study. Lancet Oncol 17 (9): 1240–1247.
102 102 Lin, G.W., Xu, C., Chen, K. et al. (2020). Genetic risk of extranodal natural killer T‐cell lymphoma: a genome‐wide association study in multiple populations. Lancet Oncol 21 (2): 306–316.
103 103 Di Sabatino, A., Biagi, F., Gobbi, P.G., and Corazza, G.R. (2012). How I treat enteropathy‐associated T‐cell lymphoma. Blood 119 (11): 2458–2468.
104 104 de Leval, L. (2019). Breast implant‐associated anaplastic large cell lymphoma and other rare T‐cell lymphomas. Hematol Oncol 37 (S1): 24–29.
105 105 Laurent, C., Haioun, C., Brousset, P., and Gaulard, P. (2018). New insights into breast implant‐associated anaplastic large cell lymphoma. Curr Opin Oncol 30 (5): 292–300.
106 106 McGirt, L.Y., Jia, P., Baerenwald, D.A. et al. (2015). Whole‐genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 126 (4): 508–519.
107 107 Inoue, S., Li, W.Y., Tseng, A. et al. (2016). Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 30 (2): 337–348.
108 108 Sulkowski, P.L., Corso, C.D., Robinson, N.D. et al. (2017). 2‐Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 9: 375, eaal2463.
109 109 Cimmino,
